Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors Buyback Yield % Chart
For the Asset Management subindustry, abrdn Life Sciences Investors's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
abrdn Life Sciences Investors Buyback Yield % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where abrdn Life Sciences Investors's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors (HQL) has a Buyback Yield % of 0.00 as of Aug. 20, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on abrdn Life Sciences Investors and its competitors. According to the industry distribution chart, abrdn Life Sciences Investors ranks #999999 out of 750 companies in the Asset Management industry.
Is abrdn Life Sciences Investors' Buyback Yield % too high?
abrdn Life Sciences Investors' current Buyback Yield % is 0.00. Based on the distribution chart, abrdn Life Sciences Investors ranks #999999 out of 750 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' Buyback Yield % compare to IIM and NOAH?
According to the Asset Management industry distribution chart, abrdn Life Sciences Investors ranks #999999 out of 750 companies for Buyback Yield %. This places abrdn Life Sciences Investors in the lower half of its industry. The industry median Buyback Yield % is 0.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for an Asset Management company?
The median Buyback Yield % among Asset Management companies is 0.26, based on 750 companies in the industry. Companies in the top quartile (top 25%) have a Buyback Yield % significantly above this median, while those in the bottom quartile fall well below. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on abrdn Life Sciences Investors and its competitors. For the Asset Management industry, the median Buyback Yield % is 0.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. abrdn Life Sciences Investors's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $22.11 — trading 64.3% below its estimated fair value. The current Buyback Yield % is 0.00. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current Buyback Yield % is 0.00 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?
Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued.
The current stock price of $22.11 is trading 64.3% below its estimated GF Value™ of $62.01.
GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.
Key valuation signals for HQL:
Buyback Yield %: 0.00
GF Value™: $62.01 vs. price of $22.11 (64.3% below fair value)
No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score
Get the complete analysis for HQL
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HQL has been successfully added to your 
